<DOC>
	<DOCNO>NCT02856048</DOCNO>
	<brief_summary>The purpose study determine efficacy temporary ovarian suppression obtain administration gonadotropin release hormone agonist alkylating agent contain chemotherapy ovarian reserve assess Anti-Müllerian hormone ( AMH ) serum level adolescent young woman cancer .</brief_summary>
	<brief_title>Co-treatment With GnRH Analogs Ovarian Reserve Young Women Treated With Alkylating Agents Cancer</brief_title>
	<detailed_description>This French , Prospective , Multicentre , Open , Randomised study To determine efficacy temporary ovarian suppression obtain administration Gonadotropin Releasing Hormone agonist ( GnRHa ) maintain ovarian reserve , patient randomize , half receive Triptorelin extend release ( LP ) 3 mg intramuscularly every 28±3 day , start inclusion visit least 72 day chemotherapy alkylating agent 1 month end chemotherapy ( mean duration : 12 month ) . The primary objective study determine effect temporary ovarian suppression achieve administration gonadotropin release hormone agonist ( triptorelin LP 3 mg ) alkylating agent contain chemotherapy ovarian reserve assess AMH serum level adolescent young woman cancer . Number centre 19 Research period - Recruitment duration 2 year - The duration participation patient : 3 year - The duration treatment period : 1 year - The duration follow-up period : 2 year - Total duration : 5 year Statistical analysis : 1 . Sample size design One Hundred sixty ( 160 ) patient include study order ensure least 128 patient complete study . This number patient allow u identify power 80 % difference 5 pmol/L AMH serum level two group , accept risk alpha 0.05 . 2 . Analysis populations The main analysis intention-to-treat ( ITT ) analysis , perform randomized patient value main criterion judgment ( AMH level M24 ) . A per-protocol ( PP ) analysis also perform , secondary analysis , exclude patient major protocol deviation define priori . 3 . Primary criterion The value AMH level month 24will compare two treatment group use test Student AMH value normally distribute non-parametric Wilcoxon test .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Alkylating Agents</mesh_term>
	<criteria>Female age 12 25 year Puberty Tanner 2 Diagnosis cancer : Sarcoma , Ewing , Osteosarcoma , Lymphoma Chemotherapy protocol alkylating agent intermediate ovarian toxicity risk ( Cyclophosphamide 6 g/m2 , Ifosfamide 50 g/m2 , Procarbazine 4 g/m2 , Lomustine 350 mg/m2 Melphalan 140 mg/m2 combination drug ) . All patient osteosarcoma , Ewing sarcoma except pelvic localisation , Hodgkin lymphoma treatment group III ( stage II B , III B IV ) , B cell lymphoma group C , rhabdomyosarcoma treat least 8 Ifosfamide Vincristin Actinomycin ( IVA ) course , synoviosarcoma group II T &gt; 5 cm group III , adult type sarcoma group I II T &gt; 5 cm group III . Before start chemotherapy Covered medical insurance Prepubertal Pregnant Planned brain pelvic radiotherapy Planned stem cell transplantation Ovariectomy Having already receive chemotherapy alkylating agent Hypersensitivity component GnRHa</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GnRH agonist</keyword>
	<keyword>Ovarian reserve</keyword>
	<keyword>Fertility Preservation</keyword>
	<keyword>Alkylating Agents</keyword>
</DOC>